{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:42:12Z","timestamp":1789782132382,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX113-11133NI"],"award-info":[{"award-number":["NHRI-EX113-11133NI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-114-188"],"award-info":[{"award-number":["DMR-114-188"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2314-B-182A-024-MY3"],"award-info":[{"award-number":["MOST 111-2314-B-182A-024-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8M1311, CMRPG8M1361, CMRPG8N1201, CMRPG8N1121, CMRPG8N1212"],"award-info":[{"award-number":["CMRPG8M1311, CMRPG8M1361, CMRPG8N1201, CMRPG8N1121, CMRPG8N1212"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8M1311, CMRPG8M1361, CMRPG8N1201, CMRPG8N1121, CMRPG8N1212"],"award-info":[{"award-number":["CMRPG8M1311, CMRPG8M1361, CMRPG8N1201, CMRPG8N1121, CMRPG8N1212"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03492-3","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T04:29:32Z","timestamp":1754368172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sodium benzoate treatment decreased amyloid beta peptides and improved cognitive function among patients with Alzheimer\u2019s disease: secondary analysis of a randomized clinical trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-6964","authenticated-orcid":false,"given":"Chieh-Hsin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2162-8174","authenticated-orcid":false,"given":"Hsien-Yuan","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"3492_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(08)70170-4","volume":"7","author":"T Wisniewski","year":"2008","unstructured":"Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimer\u2019s disease. Lancet Neurol. 2008;7:805\u201311.","journal-title":"Lancet Neurol"},{"key":"3492_CR2","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/brain\/awad159","volume":"146","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Robakis NK, Hoilund-Carlsen PF, Sensi SL, Vissel B. The amyloid cascade hypothesis: an updated critical review. Brain. 2023;146:3969\u201390.","journal-title":"Brain"},{"key":"3492_CR3","doi-asserted-by":"publisher","first-page":"NS20220086","DOI":"10.1042\/NS20220086","volume":"7","author":"C Weglinski","year":"2023","unstructured":"Weglinski C, Jeans A. Amyloid-beta in Alzheimer\u2019s disease - front and centre after all? Neuronal Signal. 2023;7:NS20220086.","journal-title":"Neuronal Signal"},{"key":"3492_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1212\/WNL.0000000000207873","volume":"101","author":"MD Howe","year":"2023","unstructured":"Howe MD, Rabinovici GD, Salloway SP. Real-world application of anti-beta-amyloid monoclonal antibodies: untangling eligibility. Neurology. 2023;101:811\u20132.","journal-title":"Neurology"},{"key":"3492_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/brain\/awad005","volume":"146","author":"R Perneczky","year":"2023","unstructured":"Perneczky R, Jessen F, Grimmer T, Levin J, Floel A, Peters O, et al. Anti-amyloid antibody therapies in Alzheimer\u2019s disease. Brain. 2023;146:842\u20139.","journal-title":"Brain"},{"key":"3492_CR6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","volume":"29","author":"WK Self","year":"2023","unstructured":"Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med. 2023;29:2187\u201399.","journal-title":"Nat Med"},{"key":"3492_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1474-4422(23)00449-0","volume":"23","author":"J Delrieu","year":"2024","unstructured":"Delrieu J, Andrieu S, Vellas B. Dementia research in 2023: the year of anti-amyloid immunotherapy. Lancet Neurol. 2024;23:13\u201315.","journal-title":"Lancet Neurol"},{"key":"3492_CR8","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1002\/alz.12833","volume":"19","author":"UK Adhikari","year":"2023","unstructured":"Adhikari UK, Khan R, Mikhael M, Balez R, David MA, Mahns D, et al. Therapeutic anti-amyloid beta antibodies cause neuronal disturbances. Alzheimers Dement. 2023;19:2479\u201396.","journal-title":"Alzheimers Dement"},{"key":"3492_CR9","volume":"20","author":"R Brockmann","year":"2023","unstructured":"Brockmann R, Nixon J, Love BL, Yunusa I. Impacts of FDA approval and medicare restriction on antiamyloid therapies for Alzheimer\u2019s disease: patient outcomes, healthcare costs, and drug development. Lancet Reg Health Am. 2023;20:100467.","journal-title":"Lancet Reg Health Am"},{"key":"3492_CR10","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324.","journal-title":"Brain"},{"key":"3492_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102012","volume":"90","author":"D Jeremic","year":"2023","unstructured":"Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L. Efficacy and safety of anti-amyloid-beta monoclonal antibodies in current Alzheimer\u2019s disease phase III clinical trials: a systematic review and interactive web app-based meta-analysis. Ageing Res Rev. 2023;90:102012.","journal-title":"Ageing Res Rev"},{"key":"3492_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs. 2024;38:5\u201322.","journal-title":"BioDrugs"},{"key":"3492_CR13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1126\/science.adj9255","volume":"382","author":"TE Golde","year":"2023","unstructured":"Golde TE, Levey AI. Immunotherapies for Alzheimer\u2019s disease. Science. 2023;382:1242\u20134.","journal-title":"Science"},{"key":"3492_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","volume":"101","author":"VK Ramanan","year":"2023","unstructured":"Ramanan VK, Armstrong MJ, Choudhury P, Coerver KA, Hamilton RH, Klein BC, et al. Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology. Neurology. 2023;101:842\u201352.","journal-title":"Neurology"},{"key":"3492_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid beta-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8:248.","journal-title":"Signal Transduct Target Ther"},{"key":"3492_CR16","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.4049\/jimmunol.0803336","volume":"183","author":"S Brahmachari","year":"2009","unstructured":"Brahmachari S, Jana A, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol. 2009;183:5917\u201327.","journal-title":"J Immunol"},{"key":"3492_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11481-011-9286-3","volume":"7","author":"S Khasnavis","year":"2012","unstructured":"Khasnavis S, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons. J Neuroimmune Pharmacol. 2012;7:424\u201335.","journal-title":"J Neuroimmune Pharmacol"},{"key":"3492_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/ijms23010192","volume":"23","author":"SB Rangasamy","year":"2021","unstructured":"Rangasamy SB, Raha S, Dasarathy S, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, improves cognitive functions in mice after controlled cortical impact injury. Int J Mol Sci. 2021;23:192.","journal-title":"Int J Mol Sci"},{"key":"3492_CR19","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.ymgme.2003.11.017","volume":"81","author":"F Scaglia","year":"2004","unstructured":"Scaglia F, Carter S, O\u2019Brien WE, Lee B. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab. 2004;81:S79\u201385.","journal-title":"Mol Genet Metab"},{"key":"3492_CR20","doi-asserted-by":"publisher","first-page":"e0130398","DOI":"10.1371\/journal.pone.0130398","volume":"10","author":"KK Modi","year":"2015","unstructured":"Modi KK, Roy A, Brahmachari S, Rangasamy SB, Pahan K. Cinnamon and its metabolite sodium benzoate attenuate the activation of p21rac and protect memory and learning in an animal model of Alzheimer\u2019s disease. PLoS ONE. 2015;10:e0130398.","journal-title":"PLoS ONE"},{"key":"3492_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.biopsych.2013.08.010","volume":"75","author":"CH Lin","year":"2014","unstructured":"Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2014;75:678\u201385.","journal-title":"Biol Psychiatry"},{"key":"3492_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/pcn.13504","volume":"77","author":"HY Lane","year":"2023","unstructured":"Lane HY, Wang SH, Lin CH. Endogenous antioxidants predicted outcome and increased after treatment: a benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer\u2019s disease. Psychiatry Clin Neurosci. 2023;77:102\u20139.","journal-title":"Psychiatry Clin Neurosci"},{"key":"3492_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/ijnp\/pyab001","volume":"24","author":"HY Lane","year":"2021","unstructured":"Lane HY, Tu CH, Lin WC, Lin CH. Brain activity of benzoate, a D-Amino acid oxidase inhibitor, in patients with mild cognitive impairment in a randomized, double-blind, placebo controlled clinical trial. Int J Neuropsychopharmacol. 2021;24:392\u20139.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3492_CR24","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","volume":"61","author":"R Mayeux","year":"2003","unstructured":"Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: relation to age, mortality, and risk. Neurology. 2003;61:1185\u201390.","journal-title":"Neurology"},{"key":"3492_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"3492_CR26","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412\u20134.","journal-title":"Neurology"},{"key":"3492_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"3492_CR28","first-page":"627","volume":"24","author":"RC Mohs","year":"1988","unstructured":"Mohs RC, Cohen L. Alzheimer\u2019s disease assessment scale (ADAS). Psychopharmacol Bull. 1988;24:627\u20138.","journal-title":"Psychopharmacol Bull"},{"key":"3492_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.14283\/jpad.2019.27","volume":"6","author":"TM Solomon","year":"2019","unstructured":"Solomon TM, Barbone JM, Feaster HT, Miller DS, deBros GB, Murphy CA, et al. Comparing the standard and electronic versions of the Alzheimer\u2019s disease assessment scale - cognitive subscale: a validation study. J Prev Alzheimers Dis. 2019;6:237\u201341.","journal-title":"J Prev Alzheimers Dis"},{"key":"3492_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1212\/01.wnl.0000191403.95453.6a","volume":"66","author":"ME Gurol","year":"2006","unstructured":"Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66:23\u201329.","journal-title":"Neurology"},{"key":"3492_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13195-020-00696-1","volume":"12","author":"S Lehmann","year":"2020","unstructured":"Lehmann S, Dumurgier J, Ayrignac X, Marelli C, Alcolea D, Ormaechea JF, et al. Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer\u2019s disease and are highly correlated with phospho-tau in control individuals. Alzheimers Res Ther. 2020;12:123.","journal-title":"Alzheimers Res Ther"},{"key":"3492_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2023.125357","volume":"268","author":"A Cournut","year":"2024","unstructured":"Cournut A, Moustiez P, Coffinier Y, Enjalbal C, Bich C. Innovative SALDI mass spectrometry analysis for Alzheimer\u2019s disease synthetic peptides detection. Talanta. 2024;268:125357.","journal-title":"Talanta"},{"key":"3492_CR33","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1089\/ars.2012.5027","volume":"19","author":"DA Butterfield","year":"2013","unstructured":"Butterfield DA, Swomley AM, Sultana R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. 2013;19:823\u201335.","journal-title":"Antioxid Redox Signal"},{"key":"3492_CR34","doi-asserted-by":"publisher","first-page":"38847","DOI":"10.1021\/acsomega.2c04583","volume":"7","author":"JM Shi","year":"2022","unstructured":"Shi JM, Li HY, Liu H, Zhu L, Guo YB, Pei J, et al. N-terminal domain of amyloid-beta impacts fibrillation and neurotoxicity. ACS Omega. 2022;7:38847\u201355.","journal-title":"ACS Omega"},{"key":"3492_CR35","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00726-023-03349-3","volume":"55","author":"I Sanchis","year":"2023","unstructured":"Sanchis I, Spinelli R, Siano A. Acetylcholine hydrolytic activity of fibrillated beta-amyloid (1-40) peptide. Amino Acids. 2023;55:1991\u20137.","journal-title":"Amino Acids"},{"key":"3492_CR36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12035-014-9053-6","volume":"53","author":"PK Kamat","year":"2016","unstructured":"Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C, et al. Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer\u2019s disease: understanding the therapeutics strategies. Mol Neurobiol. 2016;53:648\u201361.","journal-title":"Mol Neurobiol"},{"key":"3492_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1081938","volume":"17","author":"MO Iliyasu","year":"2023","unstructured":"Iliyasu MO, Musa SA, Oladele SB, Iliya AI. Amyloid-beta aggregation implicates multiple pathways in Alzheimer\u2019s disease: understanding the mechanisms. Front Neurosci. 2023;17:1081938.","journal-title":"Front Neurosci"},{"key":"3492_CR38","doi-asserted-by":"publisher","first-page":"115288","DOI":"10.1016\/j.psychres.2023.115288","volume":"326","author":"HY Lane","year":"2023","unstructured":"Lane HY, Wang SH, Lin CH. Differential relationships of NMDAR hypofunction and oxidative stress with cognitive decline. Psychiatry Res. 2023;326:115288.","journal-title":"Psychiatry Res"},{"key":"3492_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.cdd.4401528","volume":"12","author":"H Kadowaki","year":"2005","unstructured":"Kadowaki H, Nishitoh H, Urano F, Sadamitsu C, Matsuzawa A, Takeda K, et al. Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ. 2005;12:19\u201324.","journal-title":"Cell Death Differ"},{"key":"3492_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","volume":"14","author":"C Cheignon","year":"2018","unstructured":"Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease. Redox Biol. 2018;14:450\u201364.","journal-title":"Redox Biol"},{"key":"3492_CR41","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/ijms22052283","volume":"22","author":"YJ Cheng","year":"2021","unstructured":"Cheng YJ, Lin CH, Lane HY. Involvement of cholinergic, adrenergic, and glutamatergic network modulation with cognitive dysfunction in Alzheimer\u2019s disease. Int J Mol Sci. 2021;22:2283.","journal-title":"Int J Mol Sci"},{"key":"3492_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2024.173885","volume":"245","author":"HY Lane","year":"2024","unstructured":"Lane HY, Wang SH, Lin CH. Sex- and dose-dependent catalase increase and its clinical impact in a benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer\u2019s disease. Pharmacol Biochem Behav. 2024;245:173885.","journal-title":"Pharmacol Biochem Behav"},{"key":"3492_CR43","doi-asserted-by":"publisher","first-page":"423","DOI":"10.9758\/cpn.2021.19.3.423","volume":"19","author":"TI Chiang","year":"2021","unstructured":"Chiang TI, Yu YH, Lin CH, Lane HY. Novel biomarkers of Alzheimer\u2019s disease: based upon N-methyl-D-aspartate receptor hypoactivation and oxidative stress. Clin Psychopharmacol Neurosci. 2021;19:423\u201333.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"3492_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4103\/1735-5362.213984","volume":"12","author":"R Arabsolghar","year":"2017","unstructured":"Arabsolghar R, Saberzadeh J, Khodaei F, Borojeni RA, Khorsand M, Rashedinia M. The protective effect of sodium benzoate on aluminum toxicity in PC12 cell line. Res Pharm Sci. 2017;12:391\u2013400.","journal-title":"Res Pharm Sci"},{"key":"3492_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fnmol.2019.00105","volume":"12","author":"W Xu","year":"2019","unstructured":"Xu W, Li T, Gao L, Lenahan C, Zheng J, Yan J, et al. Sodium benzoate attenuates secondary brain injury by inhibiting neuronal apoptosis and reducing mitochondria-mediated oxidative stress in a rat model of intracerebral hemorrhage: possible involvement of DJ-1\/Akt\/IKK\/NFkappaB pathway. Front Mol Neurosci. 2019;12:105.","journal-title":"Front Mol Neurosci"},{"key":"3492_CR46","doi-asserted-by":"publisher","first-page":"e22720","DOI":"10.1002\/jbt.22720","volume":"35","author":"E Angelopoulou","year":"2021","unstructured":"Angelopoulou E, Paudel YN, Piperi C, Mishra A. Neuroprotective potential of cinnamon and its metabolites in Parkinson\u2019s disease: mechanistic insights, limitations, and novel therapeutic opportunities. J Biochem Mol Toxicol. 2021;35:e22720.","journal-title":"J Biochem Mol Toxicol"},{"key":"3492_CR47","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.biopsych.2017.12.006","volume":"84","author":"CH Lin","year":"2018","unstructured":"Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Yang HT, et al. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2018;84:422\u201332.","journal-title":"Biol Psychiatry"},{"key":"3492_CR48","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s11064-017-2367-9","volume":"42","author":"E Howley","year":"2017","unstructured":"Howley E, Bestwick M, Fradley R, Harrison H, Leveridge M, Okada K, et al. Assessment of the target engagement and D-serine biomarker profiles of the D-amino acid oxidase inhibitors sodium benzoate and PGM030756. Neurochem Res. 2017;42:3279\u201388.","journal-title":"Neurochem Res"},{"key":"3492_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41537-025-00604-2","volume":"11","author":"CH Chang","year":"2025","unstructured":"Chang CH, Hsia YD, Liu WC, Lee JH, Lin CH, Lane HY. Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials. Schizophrenia (Heidelb). 2025;11:73.","journal-title":"Schizophrenia (Heidelb)"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03492-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03492-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03492-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:53:34Z","timestamp":1757343214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03492-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3492"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03492-3","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital, Taiwan (201405724A3C504), Institutional Review Board of China Medical University Hospital, Taiwan (CMUH104\u2010REC2\u2010090) and Institutional Review Board of Tsaotun Psychiatric Center, Taiwan (104039).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}}],"article-number":"264"}}